The emergence of mephedrone along with other artificial cathinones has introduced issues for lawmakers and regulatory organizations tasked with controlling the proliferation of recent psychoactive substances. The dynamic nature of artificial drug manufacturing, coupled with the flexibility of chemists to change molecular constructions to evade lawf